Study wrapper · #732
MOTS-c attenuates cardiac dysfunction following high altitude exposure by promoting mitophagy.
Editor's note
This study modelled high-altitude cardiac dysfunction in mice and found it persisted after return to lower altitude, alongside sustained MOTS-c deficiency. Exogenous MOTS-c during de-acclimatisation improved cardiac function by activating the Pink1/Parkin mitophagy pathway; silencing Pink1 abolished the benefit, a solid causal check. The authors also observed lower circulating MOTS-c in patients with high-altitude heart disease and acute coronary syndrome, an association, not proof. This is primarily a single-model preclinical study; these are preclinical findings, and human data are needed before any clinical conclusions. It reinforces MOTS-c's recurring role in maintaining mitochondrial quality through mitophagy in stressed hearts, a coherent mechanism that nonetheless awaits human interventional testing.
Plain-language abstract
Spending time at high altitude can strain the heart, and some of that strain lingers even after coming back down. Researchers simulated a 6,000-metre altitude in mice for 10 days, then a lower altitude for another 10, and found the heart dysfunction persisted along with a lasting drop in MOTS-c, a mitochondria-derived peptide. Giving MOTS-c during the recovery period improved heart function. They showed it worked by switching on the Pink1/Parkin "mitophagy" system, which clears out damaged mitochondria; when they blocked Pink1, MOTS-c stopped helping. They also noticed that people with high-altitude heart disease and acute coronary syndrome had lower blood MOTS-c, though that is just an association. Because the treatment was tested only in mice, it cannot show how MOTS-c would affect people, and human studies would be needed. The work supports the idea that MOTS-c helps hearts by keeping mitochondria healthy under stress.